• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vero/CHOK1, a novel mixture of cell lines that is optimal for the rescue of influenza A vaccine seeds

tetano

Editor, Senior Moderator
J Virol Methods. 2013 Oct 23. pii: S0166-0934(13)00394-7. doi: 10.1016/j.jviromet.2013.09.007. [Epub ahead of print]
Vero/CHOK1, a novel mixture of cell lines that is optimal for the rescue of influenza A vaccine seeds.
Medina J, Guillot V, Totain E, Rouleau M, Sodoyer R, Moste C, Legastelois I.
Source

Research and Development, Sanofi Pasteur, 1541 Avenue Marcel M?rieux, 69280 Marcy L'Etoile, France. Electronic address: julie.medina@live.fr.
Abstract

Seasonal and pandemic influenza vaccine manufacturing is challenged with a tight production schedule. Reverse genetics constitutes a rapid method for creating viruses. Vero and CHOK1 cells were found to be an appropriate cell mixture for the generation of influenza reassortants by reverse genetics under the constraints of vaccine production, such as the use of regulatory-compliant cells and culture media devoid of components of animal origin. In addition, no further amplification in cell or egg substrates was required, thus reducing the time needed to obtain reassortant seed virus. In parallel, the cloning step was shown to be dramatically improved, permitting the rapid vRNA expression of influenza viruses. In addition, nucleoporation of the cells was conducted to more efficiently target the nucleus and avoid the use of chemical reagents containing proteins of animal origin. In conclusion, the reverse genetics system for influenza A viruses reported in this study was shown to be rapid, simple to perform and totally animal component-free to best comply with the requirements of health authorities for the production of a vaccine seed.

Copyright ? 2013 Elsevier B.V. All rights reserved.
KEYWORDS:

Animal-free, CHO cells, Influenza, Reverse genetics, Vaccine

PMID:
24161812
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24161812
 
Back
Top Bottom